This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Reboxetine Treatment of Depression in Parkinson’s Disease

Matthias R. Lemke

Published: October 31, 2000

Article Abstract

Letter to the Editor

Sir: The efficacy and tolerability of reboxetine, a norepinephrine reuptake inhibitor, have been shown in patients with major depressive disorder or dysthymia. This novel antidepressant shows negligible effects on psychomotor and cognitive function and may be especially effective in improving negative self-perception and lack of motivation toward action. Depression occurs frequently in Parkinson’s disease and appears to be associated with greater frontal lobe dysfunctions, including reward and motivational systems, and greater involvement of dopaminergic and noradrenergic systems than in nondepressed Parkinson’s patients. We report for the first time reboxetine treatment of depression in Parkinson’s disease after prior treatment with amitriptyline and fluoxetine was ineffective and accompanied by intolerable side effects.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 61

Quick Links: